{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:16:54Z","timestamp":1791422214791,"version":"4.3.3"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","nanomedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.nano.2016.12.006","type":"journal-article","created":{"date-parts":[[2016,12,18]],"date-time":"2016-12-18T07:07:48Z","timestamp":1482044868000},"page":"821-828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Point of care assessment of melanoma tumor signaling and metastatic burden from \u03bcNMR analysis of tumor fine needle aspirates and peripheral blood"],"prefix":"10.1016","volume":"13","author":[{"given":"Michael S.","family":"Gee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezou A.","family":"Ghazani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Weissleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.nano.2016.12.006_bb0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.nano.2016.12.006_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2015.08.021","article-title":"Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma","author":"Carlino","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.nano.2016.12.006_bb0015","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.nano.2016.12.006_bb0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.sder.2010.06.005","article-title":"Targeted molecular therapy in melanoma","volume":"29","author":"Puzanov","year":"2010","journal-title":"Semin Cutan Med Surg"},{"issue":"6","key":"10.1016\/j.nano.2016.12.006_bb0025","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.nano.2016.12.006_bb0030","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-14-1650","article-title":"New strategies in melanoma: entering the era of combinatorial therapy","volume":"21","author":"Sullivan","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.nano.2016.12.006_bb0035","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas N","year":"2015","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.nano.2016.12.006_bb0040","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","author":"Brose","year":"2002","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.nano.2016.12.006_bb0045","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.nano.2016.12.006_bb0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"issue":"7326","key":"10.1016\/j.nano.2016.12.006_bb0055","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.nano.2016.12.006_bb0060","doi-asserted-by":"crossref","first-page":"E536","DOI":"10.1073\/pnas.1418163112","article-title":"BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model","volume":"112","author":"Perna","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"10.1016\/j.nano.2016.12.006_bb0065","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.nano.2016.12.006_bb0070","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.1711","article-title":"Chip-NMR biosensor for detection and molecular analysis of cells","volume":"14","author":"Lee","year":"2008","journal-title":"Nat Med"},{"issue":"141","key":"10.1016\/j.nano.2016.12.006_bb0075","doi-asserted-by":"crossref","first-page":"141ra92","DOI":"10.1126\/scitranslmed.3003747","article-title":"Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector","volume":"4","author":"Issadore","year":"2012","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.nano.2016.12.006_bb0080","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1039\/c4lc00314d","article-title":"Magnetic sensing technology for molecular analyses","volume":"14","author":"Issadore","year":"2014","journal-title":"Lab Chip"},{"key":"10.1016\/j.nano.2016.12.006_bb0085","doi-asserted-by":"crossref","DOI":"10.1021\/cr500698d","article-title":"Recent developments in magnetic diagnostic systems","author":"Lee","year":"2015","journal-title":"Chem Rev"},{"issue":"71","key":"10.1016\/j.nano.2016.12.006_bb0090","doi-asserted-by":"crossref","first-page":"71ra16","DOI":"10.1126\/scitranslmed.3002048","article-title":"Micro-NMR for rapid molecular analysis of human tumor samples","volume":"3","author":"Haun","year":"2011","journal-title":"Sci Transl Med"},{"issue":"51","key":"10.1016\/j.nano.2016.12.006_bb0095","doi-asserted-by":"crossref","first-page":"E4978","DOI":"10.1073\/pnas.1315370110","article-title":"Ascites analysis by a microfluidic chip allows tumor-cell profiling","volume":"110","author":"Peterson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.nano.2016.12.006_bb0100","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.nano.2013.03.011","article-title":"Comparison of select cancer biomarkers in human circulating and bulk tumor cells using magnetic nanoparticles and a miniaturized micro-NMR system","volume":"9","author":"Ghazani","year":"2013","journal-title":"Nanomedicine"},{"issue":"12","key":"10.1016\/j.nano.2016.12.006_bb0105","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS\u2013ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.nano.2016.12.006_bb0110","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1596\/neo.12696","article-title":"Sensitive and direct detection of circulating tumor cells by multimarker micro-nuclear magnetic resonance","volume":"14","author":"Ghazani","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.nano.2016.12.006_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-61779-052-2_3","article-title":"Molecular detection of biomarkers and cells using magnetic nanoparticles and diagnostic magnetic resonance","volume":"726","author":"Haun","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.nano.2016.12.006_bb0120","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"issue":"7\u20138","key":"10.1016\/j.nano.2016.12.006_bb0125","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/mrd.22489","article-title":"The ImageJ ecosystem: an open platform for biomedical image analysis","volume":"82","author":"Schingelin","year":"2015","journal-title":"Mol Reprod Dev"},{"issue":"2","key":"10.1016\/j.nano.2016.12.006_bb0130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"6892","key":"10.1016\/j.nano.2016.12.006_bb0135","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.nano.2016.12.006_bb0140","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.nano.2016.12.006_bb0145","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1158\/1535-7163.MCT-11-1010","article-title":"ERK inhibition overcomes acquired resistance to MEK inhibitors","volume":"11","author":"Hatzivassiliou","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.nano.2016.12.006_bb0150","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2147\/OTT.S72823","article-title":"New developments in the management of advanced melanoma \u2014 role of pembrolizumab","volume":"8","author":"Improta","year":"2015","journal-title":"Onco Targets Ther"},{"issue":"7","key":"10.1016\/j.nano.2016.12.006_bb0155","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S1470-2045(12)70209-7","article-title":"Circulating tumour cells in non-metastatic breast cancer: a prospective study","volume":"13","author":"Lucci","year":"2012","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.nano.2016.12.006_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju066","article-title":"Circulating tumor cells predict survival in early average-to-high risk breast cancer patients","volume":"106","author":"Rack","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.nano.2016.12.006_bb0165","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2010.28.7045","article-title":"Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer","volume":"29","author":"Krebs","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.nano.2016.12.006_bb0170","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.celrep.2014.03.039","article-title":"Isolation and molecular characterization of circulating melanoma cells","volume":"7","author":"Luo","year":"2014","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.nano.2016.12.006_bb0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2014.222","article-title":"Developing biomarker-specific end points in lung cancer clinical trials","volume":"12","author":"Neal","year":"2015","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963416302234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963416302234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T16:24:25Z","timestamp":1536164665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963416302234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1549963416302234"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2016.12.006","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Point of care assessment of melanoma tumor signaling and metastatic burden from \u03bcNMR analysis of tumor fine needle aspirates and peripheral blood","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2016.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}